F. Hoffmann-La Roche AG

Switzerland

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2017 F. Hoffmann-La Roche Ltd. All trademarks used or mentioned in this release are protected by law.

1 August 2016 - 31 July 2017

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 August 2016 - 31 July 2017 which are tracked by the Nature Index.

Hover over the donut graph to view the WFC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

AC FC WFC
78 38.24 38.24

Outputs by subject (WFC)

Subject AC FC WFC
Life Sciences 52 23.73 23.73
Chemistry 29 16.34 16.34

Highlight of the month

Immune cells worsen the effects of brain injury

<i>The Journal of Neuroscience</i> <b>36,</b> 9962–9975 (2016).

<i>The Journal of Neuroscience</i> <b>36,</b> 9962–9975 (2016).

Immune cells protect us from external threats, but when it comes to traumatic brain injury, they seem to make things worse. A German-US team, including Genentech Inc. researchers, has now shown that blocking the infiltration of immune cells from elsewhere in the body could reduce the long-term consequences of brain injury.

Repeated concussions can result in long-term damage to the whole brain – not just the site of injury, and an increased risk of dementia. To investigate this, the team subjected mice to moderate brain injuries and observed them during subsequent weeks and months.

The researchers found that any major loss of brain tissue occurred during the first few weeks close to the injured site. This was followed by more widespread inflammation in distant brain regions caused by infiltrating immune cells, and changes to some of the localized neurons. Blocking a receptor that helps recruit immune cells to the brain reduced some of this longer-term damage.

Developing drugs that target this chronic inflammation may therefore prevent the longer-term consequences of traumatic brain injuries.

Supported content

  1. © Yuri_Arcurs/E+/Getty doi: 10.1523/jneurosci.1898-15.2016

View the article on the Nature Index

1 August 2016 - 31 July 2017

International vs. domestic collaboration by WFC

  • 7.76% Domestic
  • 92.24% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the weighted fractional count (WFC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs